* Bioatla Inc BCAB.OQ BCAB.O is expected to show a rise
in
quarterly revenue when it reports results on August 9.
* The San Diego California-based company is expected to
report a
60.0% increase in revenue to $400 thousand from $250 thousand a
year ago, according to the mean estimate from 5 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for Bioatla Inc is for
a loss
of 69 cents per share. For the same quarter last year, the
company reported a loss of 90 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Bioatla Inc
is
$25, above its last closing price of $3.94.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2022 -0.67 -0.67 -0.65 Beat 3
Dec. 31 2022 -0.63 -0.63 -0.62 Beat 1.2
Sep. 30 2021 -0.63 -0.64 -0.68 Missed -5.7
Jun. 30 2021 -0.60 -0.58 -0.90 Missed -53.9
Mar. -0.49 -0.52 -0.56 Missed -7.1
31 2021
Dec. 31 2020 -0.78 -0.78 -1.50 Missed -92.6
This summary was machine generated August 6 at 02:08 GMT. All
figures in US dollars unless otherwise stated